In vitro activity of LY127935

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Beta-lactam antibiotics are crucial in treating bacterial infections.
• Emerging resistance necessitates the development of novel antimicrobial agents.
• Understanding the in vitro activity spectrum of new antibiotics is vital for clinical application.

Purpose of the Study:

• To evaluate the in vitro antimicrobial activity of LY127935.
• To compare LY127935's efficacy against cefamandole, cefoxitin, and cephalothin.
• To assess LY127935's activity against a diverse range of clinical isolates, including multidrug-resistant strains.

Main Methods:

• Microdilution susceptibility testing was employed.
• The study included 536 clinical bacterial isolates.
• Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were determined.

Main Results:

• LY127935 demonstrated potent activity against Enterobacteriaceae (MIC(90)s 0.12–8 µg/ml).
• It showed variable activity against anaerobes but was less active against Gram-positive cocci compared to other agents.
• LY127935 inhibited 82% of multidrug-resistant Enterobacteriaceae at ≤8 µg/ml and was bactericidal against most tested strains.

Conclusions:

• LY127935 exhibits a broad spectrum of activity and potent in vitro efficacy.
• Its activity against Gram-negative bacilli, including resistant strains, is noteworthy.
• LY127935 represents a promising new antibiotic candidate for clinical development.